JPMorgan Downgraded Several Biotech Stocks (ACOR, ALTH, AMAG, AMGN & VPHM)

JPMorgan downgraded several biotech stocks this morning.

Analyst, Geoffrey Meacham, cut Amgen (Nasdaq: AMGN), ViroPharma (Nasdaq: VPHM), Acorda Therapeutics (Nasdaq: ACOR), and Allos Therapeutics (Nasdaq: ALTH) from 'Overweight' to 'Neutral'.

Meachum also downgraded AMAG Pharmaceuticals (Nasdaq: AMAG) from Neutral to Underweight and slashed its price target from $20 to $12.

---

Discover Wall Street's best ratings calls with the pros - Upgrade to Ratings Insider Elite. Free Trial!

You May Also Be Interested In

• UPDATE: UBS Downgrades Wisconsin Energy (WEC) to Neutral; Taking Some Off The Table
• Nomura Securities Maintains a 'Neutral' on Tiffany & Co. (TIF); Cutting Estimates and Price Target
• UBS Maintains a 'Neutral' on Patterson Companies (PDCO); Raising 'The Bar' and Estimates

Create E-mail Alert Related Categories

Downgrades

Related Entities

JPMorgan

Add Your Comment

Name

Subject

Body

Verification can't see the text?
click here to refresh the image.
what's this?

Follow StreetInsider.com On Twitter